/BRNS
BRNS Stock - Barinthus Biotherapeutics plc
Healthcare|BiotechnologyNASDAQ
$0.74+1.04%
+$0.01 (+1.04%) • Dec 19
67
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.7
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+306.0%upside
Target: $3.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for BRNS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.73 – $0.75
TARGET (TP)$3.00
STOP LOSS$0.68
RISK/REWARD1:38.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.66
52W High$2.92
52W Low$0.64
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $14.97M | $802,000 | $44.70M | $268,000 | $4.82M |
| Gross Profit | $14.97M | $802,000 | $44.70M | $268,000 | $-9,566,000 |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | -198.4% |
| Operating Income | $-67,970,000 | $-83,914,000 | $-4,041,000 | $-45,221,000 | $-20,046,000 |
| Net Income | $-61,074,000 | $-73,347,000 | $5.34M | $-50,865,000 | $-17,706,000 |
| Net Margin | -408.0% | -9145.5% | 11.9% | -18979.5% | -367.3% |
| EPS | $-1.55 | $-1.91 | $0.14 | $-1.37 | $-2.24 |
Company Overview
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
BRNSBeat Rate
56%
Last 16 quarters
Avg Surprise
+27.8%
EPS vs Estimate
Beats / Misses
9/7
Last 12 quarters
Latest EPS
$-0.36
Q4 2025
EPS Surprise History
Q1 24
+18.2%
$-0.45vs$-0.55
Q2 24
+37.5%
$-0.40vs$-0.64
Q3 24
-2.4%
$-0.43vs$-0.42
Q4 24
+53.3%
$-0.21vs$-0.45
Q1 25
-2.0%
$-0.51vs$-0.50
Q2 25
-44.1%
$-0.49vs$-0.34
Q3 25
-79.3%
$-0.52vs$-0.29
Q4 25
+20.0%
$-0.36vs$-0.45
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Mar 19, 2026 | $-0.40 | — | — | — |
Q4 2025 | Nov 7, 2025 | $-0.45 | $-0.36 | +20.0% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-0.29 | $-0.52 | -79.3% | ✗ MISS |
Q2 2025 | May 7, 2025 | $-0.34 | $-0.49 | -44.1% | ✗ MISS |
Q1 2025 | Mar 20, 2025 | $-0.50 | $-0.51 | -2.0% | ✗ MISS |
Q4 2024 | Nov 6, 2024 | $-0.45 | $-0.21 | +53.3% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.42 | $-0.43 | -2.4% | ✗ MISS |
Q2 2024 | May 13, 2024 | $-0.64 | $-0.40 | +37.5% | ✓ BEAT |
Q1 2024 | Mar 20, 2024 | $-0.55 | $-0.45 | +18.2% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-0.62 | $-0.37 | +40.3% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.59 | $-0.62 | -5.1% | ✗ MISS |
Q1 2023 | Mar 31, 2023 | $-0.50 | $-0.48 | +4.8% | ✓ BEAT |
Q4 2022 | Dec 31, 2022 | $-0.43 | $-0.56 | -32.3% | ✗ MISS |
Q3 2022 | Sep 30, 2022 | $-0.38 | $0.22 | +157.2% | ✓ BEAT |
Q2 2022 | Jun 30, 2022 | $-0.32 | $0.41 | +227.2% | ✓ BEAT |
Q1 2022 | Mar 31, 2022 | — | $0.07 | — | — |
Q4 2021 | Dec 31, 2021 | $-0.31 | $0.07 | +121.9% | ✓ BEAT |
Q3 2021 | Sep 30, 2021 | — | $-0.13 | — | — |
Q2 2021 | Jun 30, 2021 | $-0.38 | $-0.64 | -69.8% | ✗ MISS |
Latest News
Barinthus Bio Issues Update On First-In-Human Phase 1 Trial Of VTP-1000 In Adults With Celiac Disease
➖ NeutralBenzinga•Dec 10, 2025, 01:01 PM
HC Wainwright & Co. Maintains Buy on Barinthus Biotherapeutics, Raises Price Target to $4
📈 PositiveBenzinga•Nov 17, 2025, 12:29 PM
Barinthus Biotherapeutics Q3 EPS $(0.36) Beats $(0.45) Estimate, Sales $14.969M, Same YoY
📈 PositiveBenzinga•Nov 7, 2025, 12:41 PM
ChemDiv To Continue R&D Support As Clywedog Merges With Barinthus Therapeutics; Combined Entity To Trade Under Ticker CLYD On Nasdaq
➖ NeutralBenzinga•Oct 24, 2025, 03:05 PM
Trading Halt: Halt status updated at 8:15:00 AM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Oct 7, 2025, 09:10 AM
Trading Halt: Halted at 7:55:00 a.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Oct 7, 2025, 09:10 AM
Barinthus Biotherapeutics And Clywedog Therapeutics Enters Into A Definitive All-Stock Merger Agreement To Form Combined Company; Before Transaction Closes The Combined Company May Initiate Partial Tender Offer To Purchase Up To $27M Worth Of Its Outstanding Shares Held By Barinthus Bio Shareholders
📈 PositiveBenzinga•Sep 30, 2025, 12:18 PM
Trading Halt: Halt status updated at 8:15:00 AM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Sep 30, 2025, 12:15 PM
Trading Halt: Halted at 7:55:00 a.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Sep 30, 2025, 11:55 AM
Frequently Asked Questions about BRNS
What is BRNS's current stock price?
Barinthus Biotherapeutics plc (BRNS) is currently trading at $0.74 per share. The stock has moved +1.04% today.
What is the analyst price target for BRNS?
The average analyst price target for BRNS is $3.00, based on 1 analyst.
What sector is Barinthus Biotherapeutics plc in?
Barinthus Biotherapeutics plc operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is BRNS's market cap?
Barinthus Biotherapeutics plc has a market capitalization of $0.03 billion, making it a small-cap company.
Does BRNS pay dividends?
No, Barinthus Biotherapeutics plc does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALGS
Aligos Therapeutics, Inc.
$10.68
Mkt Cap: $0.1B
CVM
CEL-SCI Corporation
$4.91
Mkt Cap: $0.0B
INMB
INmune Bio, Inc.
$1.83
Mkt Cap: $0.0B
KPTI
Karyopharm Therapeutics Inc.
$6.94
Mkt Cap: $0.1B
KZR
Kezar Life Sciences, Inc.
$6.34
Mkt Cap: $0.0B
MDCX
Medicus Pharma Ltd. Common Stock
$1.69
Mkt Cap: $0.0B
MRSN
Mersana Therapeutics, Inc.
$28.94
Mkt Cap: $0.1B
OKUR
OnKure Therapeutics, Inc.
$3.01
Mkt Cap: $0.0B
SNTI
Senti Biosciences, Inc.
$1.20
Mkt Cap: $0.0B
TPST
Tempest Therapeutics, Inc.
$3.12
Mkt Cap: $0.0B
Explore stocks similar to BRNS for comparison